175 related articles for article (PubMed ID: 23375327)
1. Hemojuvelin and iron metabolism in kidney and heart allograft recipients.
Przybylowski P; Koc-Zorawska E; Glowinska I; Levin-Iaina N; Macdougall IC; Malyszko JS; Mysliwiec M; Malyszko J
Transplant Proc; 2013; 45(1):391-3. PubMed ID: 23375327
[TBL] [Abstract][Full Text] [Related]
2. A possible role of hepcidin in the pathogenesis of anemia among kidney allograft recipients.
Malyszko J; Malyszko JS; Mysliwiec M
Transplant Proc; 2009 Oct; 41(8):3056-9. PubMed ID: 19857675
[TBL] [Abstract][Full Text] [Related]
3. Iron metabolism, hepcidin, and anemia in orthotopic heart transplantation recipients treated with mammalian target of rapamycin.
Przybylowski P; Malyszko JS; Macdougall IC; Malyszko J
Transplant Proc; 2013; 45(1):387-90. PubMed ID: 23375326
[TBL] [Abstract][Full Text] [Related]
4. Anemia in heart and kidney allograft recipients: is there a role for hepcidin?
Przybylowski P; Malyszko J; Malyszko JS; Koc-Zorawska E; Sadowski J; Mysliwiec M
Transplant Proc; 2010 Dec; 42(10):4255-8. PubMed ID: 21168677
[TBL] [Abstract][Full Text] [Related]
5. Growth differentiation factor 15 is related to anemia and iron metabolism in heart allograft recipients and patients with chronic heart failure.
Przybyłowski P; Wasilewski G; Bachorzewska-Gajewska H; Golabek K; Dobrzycki S; Małyszko J
Transplant Proc; 2014 Oct; 46(8):2852-5. PubMed ID: 25380934
[TBL] [Abstract][Full Text] [Related]
6. Hepcidin, iron status, and renal function in chronic renal failure, kidney transplantation, and hemodialysis.
Malyszko J; Malyszko JS; Pawlak K; Mysliwiec M
Am J Hematol; 2006 Nov; 81(11):832-7. PubMed ID: 16929540
[TBL] [Abstract][Full Text] [Related]
7. Hepcidin, an acute-phase protein and a marker of inflammation in kidney transplant recipients with and without coronary artery disease.
Malyszko J; Malyszko JS; Pawlak K; Mysliwiec M
Transplant Proc; 2006 Nov; 38(9):2895-8. PubMed ID: 17112858
[TBL] [Abstract][Full Text] [Related]
8. Is hemojuvelin a possible new player in iron metabolism in hemodialysis patients?
Malyszko J; Malyszko JS; Levin-Iaina N; Koc-Zorawska E; Kozminski P; Mysliwiec M
Int Urol Nephrol; 2012 Dec; 44(6):1805-11. PubMed ID: 22130959
[TBL] [Abstract][Full Text] [Related]
9. A possible role of hepcidin in the pathogenesis of anemia in heart allograft recipients.
Przybylowski P; Malyszko J; Malyszko JS
Transplant Proc; 2010 Jun; 42(5):1803-7. PubMed ID: 20620527
[TBL] [Abstract][Full Text] [Related]
10. Absolute and Functional Iron Deficiency Is a Common Finding in Patients With Heart Failure and After Heart Transplantation.
Przybylowski P; Wasilewski G; Golabek K; Bachorzewska-Gajewska H; Dobrzycki S; Koc-Zorawska E; Malyszko J
Transplant Proc; 2016; 48(1):173-6. PubMed ID: 26915864
[TBL] [Abstract][Full Text] [Related]
11. GDF15 is related to anemia and hepcidin in kidney allograft recipients.
Malyszko J; Koc-Zorawska E; Malyszko JS; Glowinska I; Mysliwiec M; Macdougall IC
Nephron Clin Pract; 2013; 123(1-2):112-7. PubMed ID: 23797049
[TBL] [Abstract][Full Text] [Related]
12. Possible relationship between neutrophil gelatinase-associated lipocalin, hepcidin, and inflammation in haemodialysed patients.
Malyszko J; Malyszko JS; Kozminski P; Koc-Zorawska E; Mysliwiec M; Macdougall I
Nephron Clin Pract; 2010; 115(4):c268-75. PubMed ID: 20424477
[TBL] [Abstract][Full Text] [Related]
13. YKL-40, a novel marker of cardiovascular complications, is related to kidney function in heart transplant recipients.
Przybyłowski P; Janik L; Wasilewski G; Nowak E; Koźlik P; Małyszko J
Transplant Proc; 2014 Oct; 46(8):2860-3. PubMed ID: 25380936
[TBL] [Abstract][Full Text] [Related]
14. Serum hepcidin level correlates with hyperlipidemia status in patients following allograft renal transplantation.
Xue D; He X; Zhou C
Transplant Proc; 2014; 46(1):156-9. PubMed ID: 24507043
[TBL] [Abstract][Full Text] [Related]
15. Renalase and endothelial dysfunction in heart transplant recipients.
Przybylowski P; Koc-Zorawska E; Malyszko JS; Mysliwiec M; Malyszko J
Transplant Proc; 2013; 45(1):394-6. PubMed ID: 23375328
[TBL] [Abstract][Full Text] [Related]
16. Iron regulation by hepcidin.
Zhao N; Zhang AS; Enns CA
J Clin Invest; 2013 Jun; 123(6):2337-43. PubMed ID: 23722909
[TBL] [Abstract][Full Text] [Related]
17. Iron Status and Inflammation in Early Stages of Chronic Kidney Disease.
Łukaszyk E; Łukaszyk M; Koc-Żórawska E; Tobolczyk J; Bodzenta-Łukaszyk A; Małyszko J
Kidney Blood Press Res; 2015; 40(4):366-73. PubMed ID: 26160488
[TBL] [Abstract][Full Text] [Related]
18. Iron homeostasis in heart transplant recipients randomized to ferric derisomaltose or placebo.
Brautaset Englund KV; Østby CM; Broch K; Ueland T; Aukrust P; Gude E; Andreassen AK; Gullestad L
Clin Transplant; 2022 Jul; 36(7):e14695. PubMed ID: 35532871
[TBL] [Abstract][Full Text] [Related]
19. Hepcidin and iron deficiency in pre-kidney transplant patients.
Sancho A; Pastor MC; Troya M; Bonal J; Bayés B; Morales-Indiano C; Lauzurica R; Romero R
Transplant Proc; 2009; 41(6):2079-81. PubMed ID: 19715836
[TBL] [Abstract][Full Text] [Related]
20. Effect of atorvastatin on iron metabolism regulation in patients with chronic kidney disease - a randomized double blind crossover study.
Masajtis-Zagajewska A; Nowicki M
Ren Fail; 2018 Nov; 40(1):700-709. PubMed ID: 30741616
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
